Fig. 4: Development of an integrated risk model in the discovery cohort and validation in three independent cohorts. | Nature Communications

Fig. 4: Development of an integrated risk model in the discovery cohort and validation in three independent cohorts.

From: Comprehensive analysis reveals potential therapeutic targets and an integrated risk stratification model for solitary fibrous tumors

Fig. 4: Development of an integrated risk model in the discovery cohort and validation in three independent cohorts.

a The nomogram of the integrated risk model incorporates four variables: mitotic counts, the density of Ki-67+ and CD163+ cells, and MTOR mutation. It predicts the 3-, 5-, 8-, and 10-year progression risk for each SFT patient. The importance of each variable is ranked based on the standard deviation along the nomogram scales. To use the nomogram, specific points corresponding to individual patients are located on each variable axis. The sum of these points is then located on the total points axis, and a line is drawn downward to the survival axes to determine the probability of 3-, 5-, 8-, and 10-year PFS. Kaplan–Meier plots showing PFS for SFT patients stratified by integrated risk model in: b SYSUCC cohort. c FAHSYSU cohort. d CHCAMS cohort 1. e CHCAMS cohort 2. p values were calculated using two-sided log-rank test. HR Hazard Ratio, PFS Progression Free Survival. Source data are provided as a Source Data file.

Back to article page